

GLAXOSMITHKLINE PLC

Form 6-K

October 18, 2016

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 18 October 2016

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Sir Andrew Witty
- b) Position/status Chief Executive Officer
- c) Initial notification/
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. (i) each type of transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882

- b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

	Price(s)	Volume(s)
	£17.00	370.567 (personal contribution)
	£17.00	370.555 (personal contribution)
	£17.00	185.720 (personal contribution)
	£17.00	185.720 (personal contribution)
	£17.00	465.257 (personal contribution)
c) Price(s) and volume(s)	£17.00	370.567 (matching shares)
	£17.00	370.555 (matching shares)
	£17.00	185.720 (matching shares)
	£17.00	185.720(matching shares)
	£17.00	465.257 (matching shares)

- d) Aggregated information
Aggregated volume Price

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

3155.638
£17.00

- e) Date of the transaction 2016-10-13
f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Ms E Walmsley
b) Position/status CEO Designate
c) Initial notification/
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882

- b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

- | Price(s) | Volume(s) |
|----------|---------------------------------|
| £17.00 | 81.138 (personal contribution) |
| £17.00 | 81.138 (personal contribution) |
| £17.00 | 64.694 (personal contribution) |
| £17.00 | 64.694 (personal contribution) |
| £17.00 | 160.210 (personal contribution) |
| £17.00 | 160.199 (personal contribution) |
| £17.00 | 81.138 (matching shares) |
| £17.00 | 81.138 (matching shares) |
| £17.00 | 64.694 (matching shares) |
| £17.00 | 64.694 (matching shares) |
- c) Price(s) and volume(s)

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

£17.00 160.210 (matching shares)

£17.00 160.199 (matching shares)

d) Aggregated information
Aggregated volume Price

1224.146
£17.00

e) Date of the transaction

2016-10-13

f) Place of the transaction

n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name

Mr R G Connor

b) Position/status

President, Global Manufacturing & Supply

c) Initial notification/
amendment

Initial notification

2. Details of the issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor

a) Name

GlaxoSmithKline plc

b) LEI

5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s)
has been conducted

Ordinary shares of 25 pence each
(*'Ordinary Shares'*)
ISIN: GB0009252882

a) Description of the financial instrument

b) Nature of the transaction

Increase in notional interest in Ordinary
Shares following the re-investment of
dividends paid to shareholders on 13
October 2016 on Ordinary Shares held in
the Company's 2009 Deferred Annual
Bonus Plan.

Price(s) Volume(s)

£17.00 72.533 (personal contribution)

£17.00 72.521 (personal contribution)

£17.00 47.378 (personal contribution)
 £17.00 47.378 (personal contribution)
 £17.00 108.850 (personal contribution)
 £17.00 72.533 (matching shares)
 £17.00 72.521 (matching shares)
 £17.00 47.378 (matching shares)
 £17.00 47.378 (matching shares)
 £17.00 108.850 (matching shares)

d) Aggregated information 697.320
 Aggregated volume Price £17.00

e) Date of the transaction 2016-10-13

f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr S Dingemans
 b) Position/status Chief Financial Officer

c) Initial notification/
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform,
 auctioneer or auction monitor

a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument;
 (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s)
 has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each
 ('Ordinary Shares')
 ISIN: GB0009252882

b) Nature of the transaction Increase in notional interest in Ordinary
 Shares following the re-investment of
 dividends paid to shareholders on 13

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

October 2016 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

Price(s) Volume(s)

£17.00 175.105 (personal contribution)

£17.00 70.032 (personal contribution)

£17.00 90.364 (personal contribution)

£17.00 90.352 (personal contribution)

£17.00 211.571 (personal contribution)

£17.00 211.560 (personal contribution)

c) Price(s) and volume(s)

£17.00 175.105 (matching shares)

£17.00 70.032 (matching shares)

£17.00 90.364 (matching shares)

£17.00 90.352 (matching shares)

£17.00 211.571 (matching shares)

£17.00 211.560 (matching shares)

d) Aggregated information
Aggregated volume Price

1697.968
£17.00

e) Date of the transaction

2016-10-13

f) Place of the transaction

n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name

Mr N Hirons

b) Position/status

SVP, Global Ethics & Compliance

c) Initial notification/
amendment

Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name

GlaxoSmithKline plc

b) LEI

5493000HZTVUYLO1D793

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- Details of the transaction(s): section to be repeated for (i) each type of instrument;
 3. (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882																		
b) Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.																		
c) Price(s) and volume(s)	<table border="0"> <tr> <td>Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>£17.00</td> <td>33.172 (personal contribution)</td> </tr> <tr> <td>£17.00</td> <td>33.172 (personal contribution)</td> </tr> <tr> <td>£17.00</td> <td>78.227 (personal contribution)</td> </tr> <tr> <td>£17.00</td> <td>78.227 (personal contribution)</td> </tr> <tr> <td>£17.00</td> <td>33.172 (matching shares)</td> </tr> <tr> <td>£17.00</td> <td>33.172 (matching shares)</td> </tr> <tr> <td>£17.00</td> <td>78.227 (matching shares)</td> </tr> <tr> <td>£17.00</td> <td>78.227 (matching shares)</td> </tr> </table>	Price(s)	Volume(s)	£17.00	33.172 (personal contribution)	£17.00	33.172 (personal contribution)	£17.00	78.227 (personal contribution)	£17.00	78.227 (personal contribution)	£17.00	33.172 (matching shares)	£17.00	33.172 (matching shares)	£17.00	78.227 (matching shares)	£17.00	78.227 (matching shares)
Price(s)	Volume(s)																		
£17.00	33.172 (personal contribution)																		
£17.00	33.172 (personal contribution)																		
£17.00	78.227 (personal contribution)																		
£17.00	78.227 (personal contribution)																		
£17.00	33.172 (matching shares)																		
£17.00	33.172 (matching shares)																		
£17.00	78.227 (matching shares)																		
£17.00	78.227 (matching shares)																		
d) Aggregated information	445.596																		
Aggregated volume Price	£17.00																		
e) Date of the transaction	2016-10-13																		
f) Place of the transaction	n/a																		

1. Details of PDMR/person closely associated with them ('PCA')

- | | |
|--------------------|-----------------------------------|
| a) Name | Mr S A Hussain |
| b) Position/status | President, Global Pharmaceuticals |

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

c) Initial notification/ amendment	Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted	
a) Description of the financial instrument	Ordinary shares of 25 pence each (‘Ordinary Shares’) ISIN: GB0009252882
b) Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c) Price(s) and volume(s)	Price(s) Volume(s) £17.00 106.388 (personal contribution) £17.00 156.376 (personal contribution) £17.00 184.855 (personal contribution) £17.00 184.855 (personal contribution)
	£17.00 106.388(matching shares) £17.00 156.376 (matching shares) £17.00 184.855 (matching shares) £17.00 184.855 (matching shares)
d) Aggregated information	
Aggregated volume Price	1264.948 £17.00
e) Date of the transaction	2016-10-13
f) Place of the transaction	n/a

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr D S Redfern
 - b) Position/status Chief Strategy Officer
 - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882

- b) Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

- c) Price(s) and volume(s)

Price(s)	Volume(s)
£17.00	66.155 (personal contribution)
£17.00	66.142 (personal contribution)
£17.00	53.158 (personal contribution)
£17.00	53.158 (personal contribution)
£17.00	99.557 (personal contribution)
£17.00	99.557 (personal contribution)
£17.00	66.155 (matching shares)
£17.00	66.142 (matching shares)
£17.00	53.158 (matching shares)
£17.00	53.158 (matching shares)
£17.00	99.557 (matching shares)
£17.00	99.557 (matching shares)

d) Aggregated information 875.454
 Aggregated volume Price £17.00

e) Date of the transaction 2016-10-13

f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Dr M M Slaoui

b) Position/status Chairman, Global Vaccines

c) Initial notification/
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform,
 auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument;
 (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s)
 has been conducted

a) Description of the financial instrument American Depository Shares ('ADSs')
 ISIN: US37733W1053

b) Nature of the transaction Increase in notional interest in ADSs
 following the re-investment of dividends
 paid to shareholders on 13 October 2016
 on ADSs held in the Company's 2009
 Deferred Annual Bonus Plan.

	Price(s)	Volume(s)
	\$42.39	115.213 (personal contribution)
	\$42.39	115.202 (personal contribution)
	\$42.39	71.742 (personal contribution)
	\$42.39	71.742 (personal contribution)
	\$42.39	118.095 (personal contribution)
	\$42.39	118.095 (personal contribution)
c) Price(s) and volume(s)	\$42.39	115.213 (matching shares)
	\$42.39	115.202 (matching shares)

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

\$42.39 71.742 (matching shares)

\$42.39 71.742 (matching shares)

\$42.39 118.095 (matching shares)

\$42.39 118.095 (matching shares)

d) Aggregated information
Aggregated volume Price

1220.178

\$42.39

e) Date of the transaction

2016-10-13

f) Place of the transaction

n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name

Ms C Thomas

b) Position/status

SVP, Human Resources

c) Initial notification/
amendment

Initial notification

2. Details of the issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor

a) Name

GlaxoSmithKline plc

b) LEI

5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s)
has been conducted

Ordinary shares of 25 pence each
(‘Ordinary Shares’)

a) Description of the financial instrument

ISIN: GB0009252882

b) Nature of the transaction

Increase in notional interest in Ordinary
Shares following the re-investment of
dividends paid to shareholders on 13
October 2016 on Ordinary Shares held in
the Company's 2009 Deferred Annual
Bonus Plan.

Price(s) Volume(s)

£17.00 82.083 (personal contribution)

£17.00 71.552 (personal contribution)

£17.00 71.540 (personal contribution)

c) Price(s) and volume(s)

£17.00 145.649 (personal contribution)

£17.00 145.649 (personal contribution)

£17.00 82.083 (matching shares)

£17.00 71.552 (matching shares)

£17.00 71.540 (matching shares)

£17.00 145.649 (matching shares)

£17.00 145.649 (matching shares)

d) Aggregated information 1032.946
 Aggregated volume Price £17.00

e) Date of the transaction 2016-10-13

f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr P C Thomson
 b) Position/status SVP, Communications & Government Affairs
 c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
 ISIN: GB0009252882

b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's 2009 Deferred Annual

Bonus Plan.

Price(s) Volume(s)
 £17.00 49.436 (personal contribution)

£17.00 48.598 (personal contribution)

£17.00 89.112 (personal contribution)

c) Price(s) and volume(s)

£17.00 49.436 (matching shares)

£17.00 48.598 (matching shares)

£17.00 89.112 (matching shares)

d) Aggregated information
 Aggregated volume Price

374.292
 £17.00

e) Date of the transaction

2016-10-13

f) Place of the transaction

n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr D E Troy
- b) Position/status SVP & General Counsel
- c) Initial notification/
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument American Depositary Shares ('ADSs')
 ISIN: US37733W1053

- b) Nature of the transaction Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 13 October 2016 on ADSs held in the Company's 2009 Deferred Annual Bonus Plan.

Price(s) Volume(s)
 \$42.39 46.628 (personal contribution)

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

\$42.39	46.628 (personal contribution)
\$42.39	37.123 (personal contribution)
\$42.39	37.123 (personal contribution)
\$42.39	83.585 (personal contribution)
\$42.39	83.585 (personal contribution)
\$42.39	46.628 (matching shares)
\$42.39	46.628 (matching shares)
\$42.39	37.123 (matching shares)
\$42.39	37.123 (matching shares)
\$42.39	83.585 (matching shares)
\$42.39	83.585 (matching shares)

d) Aggregated information
 Aggregated volume Price

669.344
 \$42.39

e) Date of the transaction

2016-10-13

f) Place of the transaction

n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name

Dr P J T Vallance

b) Position/status

President, Pharmaceuticals R&D

c) Initial notification/
 amendment

Initial notification

2. Details of the issuer, emission allowance market participant, auction platform,
 auctioneer or auction monitor

a) Name

GlaxoSmithKline plc

b) LEI

5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument;
 (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s)
 has been conducted

Ordinary shares of 25 pence each
 ('Ordinary Shares')
 ISIN: GB0009252882

a) Description of the financial instrument

b) Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
	Price(s) Volume(s)
	£17.00 146.682 (personal contribution)
	£17.00 146.671 (personal contribution)
	£17.00 105.324 (personal contribution)
	£17.00 105.324 (personal contribution)
	£17.00 171.329 (personal contribution)
	£17.00 171.329 (personal contribution)
c) Price(s) and volume(s)	
	£17.00 146.682 (matching shares)
	£17.00 146.671 (matching shares)
	£17.00 105.324 (matching shares)
	£17.00 105.324 (matching shares)
	£17.00 171.329 (matching shares)
	£17.00 171.329 (matching shares)
d) Aggregated information	1693.318
Aggregated volume Price	£17.00
e) Date of the transaction	2016-10-13
f) Place of the transaction	n/a

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)
Date: October 18, 2016

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc